MDM Group, Inc (OTCBB ''MDDM'') to investigate establishment of Cancer Treatment Centers in Europe
PR Newswire - May 25, 1999 10:40
DALLAS, Texas, May 25 /CNW-PRN/ - MDM Group, Inc. (OTCBB ''MDDM'') today announced that Company President, Mr. Peter Boonen, has just returned from a trip to Europe where the Company is currently examining distribution opportunities for its new Incryss International Cancer Treatments. Incryss International Inc. is the joint Cancer Treatment commercialization arm of the MDM Group and the product developer.
Mr. Boonen stated, ''This is very high on our list of objectives and, subject to forthcoming discussions with our partner and regulatory bodies, we will be establishing several Cancer Treatment Centers throughout Europe during the course of 2000.''
MDM's Cancer Treatment, known in the scientific community as a ''biologic response modifier'' (BRM), has previously returned a 41% positive response in cancer patients diagnosed as terminal and/or untreatable. The BRM has also been shown to have no toxicity or side effects, and provides every indication of establishing itself at the world forefront of cancer treatment. ''It is heartbreaking and frustrating to see people suffering and dying from many types of cancers, when we know there is something we can do for them,'' Boonen further commented.
MDM Group also advises that as production capacity will be limited during the next few years, it will initially and primarily focus on the treatment of terminal and non-responsive cancer cases.
This MDM Group objective follows the path taken by many others in making a significant product available in Europe well before regulatory approval in the USA. Examples include: the release of Hycamtin for the treatment of ovarian and small lung cancers by SmithKline Beecham (NYSE ''SBH'') and the approval to use Temodal in the treatment of brain tumors by Schering-Plough (NYSE ''SGP'').
Further, in the interests of keeping the company's shareholders better informed, the Company will issue monthly progress reports on the first working day of each month, through newswire releases, commencing July 1999. Corporate literature can be obtained at (888) 823-5767 or visit the Company website at: www.mddm.net
Note: The information contained in this release, other than historical information, may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Projections and other forward-looking statements and management expectations regarding future events and/or financial performance of the company - although given in good faith - are inherently uncertain and actual events or results may differ materially.
Inquiries for Media or Investor Relations materials, please contact the Company's Public Relations consultants at Public Image, Inc.: Tel: (604) 871-4300.
SOURCE MDM Group, Inc.
/CONTACT: Inquiries for Media or Investor Relations materials, please
contact the Company's Public Relations consultants at Public Image, Inc.: Tel:
(604) 871-4300/
(MDDM)
|
